{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:57:29Z","timestamp":1791633449309,"version":"4.3.4"},"reference-count":14,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2006,9,12]],"date-time":"2006-09-12T00:00:00Z","timestamp":1158019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2006,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Inflammatory bowel disease is associated with non\u2010adherence to treatment with oral medications.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To assess the intravenous infliximab adherence rate and identify risk factors for non\u2010adherence to treatment.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Infliximab infusion dates for 1 June 2002\u201330 October 2003 were obtained. Additional information was obtained from two other administrative and patient\u2010based databases. Non\u2010adherence was defined as a \u2018No Show\u2019 designation for a scheduled appointment. Non\u2010adherence rate, odds ratios for associations to \u2018No Show\u2019 appointments and analysis were performed to identify patient characteristics associated with non\u2010adherent behaviour.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> One thousand hundred and eighty\u2010five infliximab infusions were scheduled for 274 patients. Forty\u2010eight (4%) of appointments were classified as \u2018No Show\u2019. Six patients accounted for 13\/48 (27%) of failed appointments; another 35 patients missed one appointment. \u2018No Show\u2019 appointments were more likely to be for female patients, those on concomitant immunomodulators and those &gt;18\u2003weeks from initial infusion. Patients who missed &gt;1 appointment were more likely to be female and have Medicaid vs. those with only one missed appointment (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05). Indication, patient area code and race were not significantly associated with single or repeated No Show behaviour.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Overall, the non\u2010adherence rate for infliximab is low. Risk factors that may contribute to non\u2010adherence to treatment include female gender and maintenance dosing.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2006.03092.x","type":"journal-article","created":{"date-parts":[[2006,9,12]],"date-time":"2006-09-12T08:25:28Z","timestamp":1158049528000},"page":"1099-1103","source":"Crossref","is-referenced-by-count":45,"title":["Adherence rates with infliximab therapy in Crohn's disease"],"prefix":"10.1111","volume":"24","author":[{"given":"S.","family":"KANE","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"DIXON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,9,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00004836-198208000-00008","article-title":"Compliance to therapy in patients on a maintenance dose of sulfasalazine","volume":"4","author":"Van Hees PA","year":"1982","journal-title":"J Clin Gastroenterol"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.04683.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00467-1"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07522.x"},{"key":"e_1_2_6_8_2","article-title":"IBD disproportionately impacts women's professional and personal lives","author":"Vemupalli R","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_9_2","first-page":"12","volume-title":"Compliance in Health Care","author":"Haynes RB","year":"1979"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200101000-00015"},{"key":"e_1_2_6_11_2","first-page":"11","volume-title":"Compliance in Health Care","author":"Sackett DL","year":"1979"},{"key":"e_1_2_6_12_2","first-page":"51","volume-title":"Adherence to Treatment in Medical Conditions","author":"Nobel LM","year":"1998"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05872.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(02)05253-X"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(03)70032-9"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2006.03092.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2006.03092.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T07:10:41Z","timestamp":1697181041000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2006.03092.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,12]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10.1111\/j.1365-2036.2006.03092.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2006.03092.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,12]]}}}